Advertisement

Topics

Akebia Therapeutics, Inc.  Company Profile

19:04 EDT 21st October 2018 | BioPortfolio

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.


News Articles [797 Associated News Articles listed on BioPortfolio]

Akebia Therapeutics to merge with Keryx Biopharmaceuticals

US-based biopharmaceutical firm Akebia Therapeutics has signed a definitive agreement to merge with Keryx Biopharmaceuticals to form a fully integrated...Read More... The post Akebia Therapeutics to m...

Akebia and Keryx to merge in $1.3bn stock-for-stock agreement

Kidney disease drug developers Akebia Therapeutics Inc. and Keryx Biopharmaceuticals Inc. have agreed to merge in a deal worth $1.3bn. Keryx shareholders will receive 0.37433 common shares of Akebia f...

Akebia Therapeutics to Present at Upcoming Investor Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypox...

Akebia Therapeutics and Keryx Biopharmaceuticals to Merge

Akebia Therapeutics (NASDAQ:AKBA) and Keryx Biopharmaceuticals (NASDAQ:KERX) today announced that the companies signed, and the boards of directors of both companies have unanimously approved, a defin...

Akebia And Keryx To Merge, Establishing Critical Mass In Renal Disease

Planned all-stock transaction would bring together Akebia’s R&D organization and Keryx’s commercial apparatus for Auryxia. That drug and Akebia’s Phase...   

Akebia, Keryx announce merger

Akebia Therapeutics will enter a merger with Keryx Biopharmaceuticals in an all-stock deal that is expected to be finalized b -More- 

Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypox...

M&As this week: Cosmos Holdings, Akebia Therapeutics, Biogen

Cosmos Holdings has signed a share purchase agreement to acquire 100% interest in Cosmofarm Ltd (Cosmofarm) for an undisclosed sum. The...Read More... The post M&As this week: Cosmos Holdings, A...

PubMed Articles [448 Associated PubMed Articles listed on BioPortfolio]

Akebia quinata Decaisne aqueous extract acts as a novel anti fatigue agent in mice exposed to chronic restraint stress.

Akebia quinata Decaisne extract (AQE) (Lardizabalaceae) is used in traditional herbal medicine for stress-fatigue-related depression, improved fatigue, and mental relaxation.

Akebia saponin D reverses corticosterone hypersecretion in an Alzheimer's disease rat model.

Glucocorticoid hormones are implicated in the pathogenesis of Alzheimer's disease (AD) and other diseases including diabetes, hyperlipidemia, and osteoporosis. Akebia saponin D (ASD) possesses numerou...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Clinical Trials [158 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1263 Associated Companies listed on BioPortfolio]

Akebia Therapeutics, Inc. 

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney diseas...

Akebia Therapeutics, Inc.

Akebia Therapeutics is a discovery and development company focused on anemia and vascular disorders. Akebia’s lead program, AKB-6548, an orally bioavailable HIF-prolyl hydrox...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Akebia Therapeutics, Inc. " on BioPortfolio

We have published hundreds of Akebia Therapeutics, Inc.  news stories on BioPortfolio along with dozens of Akebia Therapeutics, Inc.  Clinical Trials and PubMed Articles about Akebia Therapeutics, Inc.  for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Akebia Therapeutics, Inc.  Companies in our database. You can also find out about relevant Akebia Therapeutics, Inc.  Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record